mirtazapine has been researched along with Congenital Myotonic Dystrophy in 1 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ramon-Duaso, C | 1 |
| Rodríguez-Morató, J | 1 |
| Selma-Soriano, E | 1 |
| Fernández-Avilés, C | 1 |
| Artero, R | 1 |
| de la Torre, R | 1 |
| Pozo, ÓJ | 1 |
| Robledo, P | 1 |
1 other study available for mirtazapine and Congenital Myotonic Dystrophy
| Article | Year |
|---|---|
Protective effects of mirtazapine in mice lacking the Mbnl2 gene in forebrain glutamatergic neurons: Relevance for myotonic dystrophy 1.
Topics: Animals; Animals, Genetically Modified; Drosophila; Female; Glutamic Acid; Male; Mice; Mice, Inbred | 2020 |